Insulin secretion predicts the response to therapy with exenatide plus pioglitazone, but not to basal/bolus insulin in poorly controlled T2DM patients: Results from the Qatar study

Muhammad A Abdul-ghani, Osama Migahid, Ayman Megahed, Rajvir Singh, Dalia Kamal, Ralph A Defronzo, Amin Jayyousi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The present study aims to identify predictors for response to combination therapy with pioglitazone plus exenatide vs basal/bolus insulin therapy in T2DM patients who are poorly controlled with maximum/near-maximum doses of metformin plus a sulfonylurea. Participants in the Qatar study received a 75-g OGTT with measurement of plasma glucose, insulin and C-peptide concentration at baseline and were then randomized to receive either treatment with pioglitazone plus exenatide or basal/bolus insulin therapy for one year. Insulin secretion measured with plasma C-peptide concentration during the OGTT was the strongest predictor of response to combination therapy (HbA1c ≤ 7.0%) with pioglitazone plus exenatide. A 54% increase in 2-hour plasma C-peptide concentration above the fasting level identified subjects who achieved the glycaemic goal (HbA1c < 7.0%) with 82% sensitivity and 79% specificity. Only baseline HbA1c was a predictor of response to basal/bolus insulin therapy. Thus, the increment in 2-hour plasma C-peptide concentration above the fasting level provides a useful tool to identify poorly controlled T2DM patients who can achieve glycaemic control without insulin therapy, and thereby, can be used to individualize antihyperglycaemic therapy in poorly controlled T2DM patients.

Original languageEnglish (US)
Pages (from-to)1075-1079
Number of pages5
JournalDiabetes, Obesity and Metabolism
Volume20
Issue number4
DOIs
StatePublished - Apr 1 2018

Fingerprint

pioglitazone
Qatar
Insulin
C-Peptide
Therapeutics
Glucose Tolerance Test
Fasting
exenatide
Metformin
Hypoglycemic Agents

Keywords

  • exenatide
  • insulin
  • insulin secretion
  • pioglitazone
  • Qatar study
  • T2DM

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Insulin secretion predicts the response to therapy with exenatide plus pioglitazone, but not to basal/bolus insulin in poorly controlled T2DM patients : Results from the Qatar study. / Abdul-ghani, Muhammad A; Migahid, Osama; Megahed, Ayman; Singh, Rajvir; Kamal, Dalia; Defronzo, Ralph A; Jayyousi, Amin.

In: Diabetes, Obesity and Metabolism, Vol. 20, No. 4, 01.04.2018, p. 1075-1079.

Research output: Contribution to journalArticle

@article{6c47787d30754c4fa033647b669c89e2,
title = "Insulin secretion predicts the response to therapy with exenatide plus pioglitazone, but not to basal/bolus insulin in poorly controlled T2DM patients: Results from the Qatar study",
abstract = "The present study aims to identify predictors for response to combination therapy with pioglitazone plus exenatide vs basal/bolus insulin therapy in T2DM patients who are poorly controlled with maximum/near-maximum doses of metformin plus a sulfonylurea. Participants in the Qatar study received a 75-g OGTT with measurement of plasma glucose, insulin and C-peptide concentration at baseline and were then randomized to receive either treatment with pioglitazone plus exenatide or basal/bolus insulin therapy for one year. Insulin secretion measured with plasma C-peptide concentration during the OGTT was the strongest predictor of response to combination therapy (HbA1c ≤ 7.0{\%}) with pioglitazone plus exenatide. A 54{\%} increase in 2-hour plasma C-peptide concentration above the fasting level identified subjects who achieved the glycaemic goal (HbA1c < 7.0{\%}) with 82{\%} sensitivity and 79{\%} specificity. Only baseline HbA1c was a predictor of response to basal/bolus insulin therapy. Thus, the increment in 2-hour plasma C-peptide concentration above the fasting level provides a useful tool to identify poorly controlled T2DM patients who can achieve glycaemic control without insulin therapy, and thereby, can be used to individualize antihyperglycaemic therapy in poorly controlled T2DM patients.",
keywords = "exenatide, insulin, insulin secretion, pioglitazone, Qatar study, T2DM",
author = "Abdul-ghani, {Muhammad A} and Osama Migahid and Ayman Megahed and Rajvir Singh and Dalia Kamal and Defronzo, {Ralph A} and Amin Jayyousi",
year = "2018",
month = "4",
day = "1",
doi = "10.1111/dom.13189",
language = "English (US)",
volume = "20",
pages = "1075--1079",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Insulin secretion predicts the response to therapy with exenatide plus pioglitazone, but not to basal/bolus insulin in poorly controlled T2DM patients

T2 - Results from the Qatar study

AU - Abdul-ghani, Muhammad A

AU - Migahid, Osama

AU - Megahed, Ayman

AU - Singh, Rajvir

AU - Kamal, Dalia

AU - Defronzo, Ralph A

AU - Jayyousi, Amin

PY - 2018/4/1

Y1 - 2018/4/1

N2 - The present study aims to identify predictors for response to combination therapy with pioglitazone plus exenatide vs basal/bolus insulin therapy in T2DM patients who are poorly controlled with maximum/near-maximum doses of metformin plus a sulfonylurea. Participants in the Qatar study received a 75-g OGTT with measurement of plasma glucose, insulin and C-peptide concentration at baseline and were then randomized to receive either treatment with pioglitazone plus exenatide or basal/bolus insulin therapy for one year. Insulin secretion measured with plasma C-peptide concentration during the OGTT was the strongest predictor of response to combination therapy (HbA1c ≤ 7.0%) with pioglitazone plus exenatide. A 54% increase in 2-hour plasma C-peptide concentration above the fasting level identified subjects who achieved the glycaemic goal (HbA1c < 7.0%) with 82% sensitivity and 79% specificity. Only baseline HbA1c was a predictor of response to basal/bolus insulin therapy. Thus, the increment in 2-hour plasma C-peptide concentration above the fasting level provides a useful tool to identify poorly controlled T2DM patients who can achieve glycaemic control without insulin therapy, and thereby, can be used to individualize antihyperglycaemic therapy in poorly controlled T2DM patients.

AB - The present study aims to identify predictors for response to combination therapy with pioglitazone plus exenatide vs basal/bolus insulin therapy in T2DM patients who are poorly controlled with maximum/near-maximum doses of metformin plus a sulfonylurea. Participants in the Qatar study received a 75-g OGTT with measurement of plasma glucose, insulin and C-peptide concentration at baseline and were then randomized to receive either treatment with pioglitazone plus exenatide or basal/bolus insulin therapy for one year. Insulin secretion measured with plasma C-peptide concentration during the OGTT was the strongest predictor of response to combination therapy (HbA1c ≤ 7.0%) with pioglitazone plus exenatide. A 54% increase in 2-hour plasma C-peptide concentration above the fasting level identified subjects who achieved the glycaemic goal (HbA1c < 7.0%) with 82% sensitivity and 79% specificity. Only baseline HbA1c was a predictor of response to basal/bolus insulin therapy. Thus, the increment in 2-hour plasma C-peptide concentration above the fasting level provides a useful tool to identify poorly controlled T2DM patients who can achieve glycaemic control without insulin therapy, and thereby, can be used to individualize antihyperglycaemic therapy in poorly controlled T2DM patients.

KW - exenatide

KW - insulin

KW - insulin secretion

KW - pioglitazone

KW - Qatar study

KW - T2DM

UR - http://www.scopus.com/inward/record.url?scp=85043506313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043506313&partnerID=8YFLogxK

U2 - 10.1111/dom.13189

DO - 10.1111/dom.13189

M3 - Article

C2 - 29227578

AN - SCOPUS:85043506313

VL - 20

SP - 1075

EP - 1079

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 4

ER -